Tag: litigation

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options

SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fiserv, Inc. (NYSE: FI) common stock between July 24, 2024 and July 22, 2025, both dates inclusive (the “Class Period”), have until September 22, 2025 to seek appointment as lead plaintiff of the Fiserv class action lawsuit. Captioned City of Hollywood Police Officers’ Retirement System v. Fiserv, Inc., No. 25-cv-06094 (S.D.N.Y.), the Fiserv class action lawsuit charges Fiserv and certain of Fiserv’s top current and former executives with violations of the Securities Exchange Act of 1934.

FLOYD, Va. and INDEPENDENCE, Va., July 28, 2025 (GLOBE NEWSWIRE) -- Skyline Bankshares, Inc. (the “Company”) (OTC QX: SLBK) – the holding company for Skyline National Bank (the “Bank”) – announced its results of operations for the second quarter of 2025.  

FORT WAYNE, Ind., July 28, 2025 (GLOBE NEWSWIRE) -- Franklin Electric Co., Inc. (NASDAQ: FELE) announced today that its Board of Directors declared a quarterly cash dividend of $0.265 per share payable August 21, 2025, to shareholders of record on August 7, 2025.

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.